Estrella Immunopharma (ESLA) is a small-cap, clinical-stage biopharmaceutical subsidiary focused on developing ARTEMIS T-cell therapies for cancers and autoimmune diseases with no revenue, significant losses, sparse analyst coverage, and high volatility typical of early-stage biotech stocks.
Fact: ESLA trades on NASDAQ with a 52-week range of approximately $0.73 to $3.15 and low average daily volume around 38,000 shares. Yahoo Finance ESLA Quote
Interpretation: The stock exhibits high volatility characteristic of micro-cap clinical-stage biotechs, with periods of sharp gains or losses often driven by clinical trial news or market sentiment rather than fundamentals.
Uncertainty/Data Limitation: Detailed historical price charts and performance metrics (e.g., YTD or multi-year returns) are available on financial platforms but subject to real-time market fluctuations; limited trading history as a public entity post-2022 restructuring may skew long-term comparisons.
Fact: The company reports no revenue (TTM), a trailing twelve-month net loss of approximately $13.25 million, diluted EPS of -$0.34, cash and equivalents of about $1.93 million (most recent quarter), and negative return on assets around -271%.
| Metric | Value (TTM or Recent) | Source/Notes |
|---|---|---|
| Revenue | $0 (no revenue reported) | Pre-commercial clinical stage |
| Net Income (Loss) | -$13.25M | Primarily R&D and operating expenses |
| EPS (Diluted) | -$0.34 | Reflects ongoing losses |
| Cash Position | ~$1.93M | Limited runway typical for small biotechs |
| Market Cap | ~$32M - $36M (approximate range) | Fluctuates with share price |
Interpretation: As a development-stage company, ESLA is burning cash on clinical development with no product sales, making it highly dependent on future financing, partnerships, or trial successes for survival.
Uncertainty/Data Limitation: Financial data is derived from public filings and aggregator sites as of mid-2026; exact quarterly breakdowns, balance sheet details, or forward projections are limited due to minimal analyst following and the company's small size. Assumptions include standard biotech accounting where R&D expenses dominate. Yahoo Finance Financials | Nasdaq ESLA Page
Fact: Analyst coverage is extremely limited; one recent rating from D. Boral Capital (February 2026) maintains a Buy rating with a price target of $8.00. Some aggregator sites list a consensus around Hold or note sparse "Strong Buy" mentions, but no broad Wall Street consensus exists.
| Analyst/Firm | Rating | Price Target | Date | Notes |
|---|---|---|---|---|
| D. Boral Capital | Buy | $8.00 | Feb 9, 2026 | Maintained; one of very few active ratings |
Interpretation: The high target relative to market cap suggests optimism about clinical pipeline potential if trials succeed, but the single rating indicates low institutional interest or visibility.
Uncertainty/Data Limitation: With minimal coverage (often 1 or fewer active analysts), consensus ratings on sites like Yahoo, TipRanks, or MarketBeat may be unreliable or based on outdated/automated data. No earnings estimates or broad forecasts available. Flag: Data reflects limited public analyst activity as of July 2026. Yahoo Analyst Page | MarketBeat ESLA
Fact: As a pre-commercial clinical-stage company, ESLA has no traditional product customers or revenue-generating sales. It maintains a collaborative agreement with Imugene Limited for solid tumor treatments combining CF33-CD19t with EB103, and is a subsidiary of Eureka Therapeutics, Inc.
Interpretation: Success depends on clinical data attracting larger pharma partners for commercialization rather than direct customer acquisition at this stage.
Uncertainty/Data Limitation: Partnership details are from company disclosures but may evolve; no public customer contracts or revenue streams confirmed. Yahoo Company Profile
Fact: ESLA competes in the T-cell therapy space (primarily CAR-T and engineered T-cell platforms targeting CD19/CD22) against established players in oncology and autoimmune indications.
| Competitor | Ticker | Focus Area | Stage/Notes |
|---|---|---|---|
| Kite Pharma (Gilead) | GILD | CAR-T (Yescarta for DLBCL) | Commercialized; larger scale |
| Novartis | NVS | CAR-T (Kymriah) | Approved therapies |
| Bristol Myers Squibb (Juno) | BMY | CAR-T pipeline | Multiple candidates |
| Other biotechs (e.g., Allogene, Legend Biotech) | Various | Allogeneic/off-the-shelf T-cell therapies | Clinical stage, similar risks |
Interpretation: ESLA's ARTEMIS platform (dual CD19/CD22 targeting) may offer differentiation in safety or efficacy for certain patients, but it faces intense competition from larger, better-funded entities with approved products.
Uncertainty/Data Limitation: Competitor landscape is broad and dynamic; exact direct comparables depend on specific indications. Data drawn from industry knowledge and public profiles; smaller peers may not be fully listed. Company Website
Fact: Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company developing T-cell therapies using its proprietary ARTEMIS cell receptor platform for blood cancers (e.g., diffuse large B-cell lymphoma) and solid tumors, as well as autoimmune diseases (e.g., systemic lupus erythematosus). Lead candidates: EB103 (Phase I/II), EB104 and EB201 (pre-clinical). Headquartered in Emeryville, CA; subsidiary of Eureka Therapeutics. Full Profile
Fact: Founded in 2006 (with roots in Eureka Therapeutics); restructured or publicly listed aspects noted around 2022. Focus has remained on engineered T-cell platforms for oncology and immunology. Robinhood Overview
Interpretation: The company's evolution reflects typical biotech spin-out or subsidiary models aiming for independent clinical advancement.
Uncertainty/Data Limitation: As a micro-cap stock, news flow is sporadic and often tied to SEC filings or trial data releases rather than frequent corporate announcements. Always verify latest developments directly from company or regulatory sources.
Overall Data Notes: All information is aggregated from public financial websites and company disclosures as of July 2026. Biotech investments carry high uncertainty due to clinical, regulatory, and financing risks. This analysis does not constitute investment advice. Verify all data with primary sources before making decisions. Stock performance excludes any specific price quotes per guidelines.